Received 31 March 2004; received in revised form 4 June 2004; accepted 4 June 2004. published online 19 August 2004.
Abstract
Classical galactosemia is an autosomal recessively inherited disorder of galactose metabolism. Treatment consists of life-long dietary restriction of galactose. Despite treatment, long-term complications occur such as a decreased bone mineral density (BMD). A decreased BMD might be the result of either dietary deficiencies secondary to the galactose-restricted diet or unknown intrinsic factors. In this study, 40 children with classical galactosemia (13 males and 27 females, aged 3–17 years) on dietary treatment were included to gain insight in the bone metabolism of galactosemics. We found weight and height Z scores significantly decreased in galactosemics. Mean areal BMD Z scores of lumbar spine and of femoral neck as measured by Dual energy X-ray Absorptiometry (DXA) were −0.6 (P < 0.001) and −0.3 (P = 0.066), respectively. Mean volumetric BMD of the femoral neck was significant lower in galactosemics (P < 0.001). The recommended dietary allowances (RDA) for calcium, magnesium, zinc, vitamin D, and protein were met in all patients. Mean serum levels of calcium, phosphate, magnesium, zinc, 1,25-dihydroxy vitamin D (1,25OHD), parathormone (PTH), 17-beta estradiol, bone alkaline phosphatase (BAP), and under-carboxylated osteocalcin (ucOC) were normal. Serum levels of IGF-1 Z score, carboxylated osteocalcin (cOC), N-terminal telopeptide (NTX), and C-terminal telopeptide (CTX) were significantly lower in galactosemics than in control subjects. The different bone markers were strongly correlated. The low levels of IGF-1 Z score, formation marker cOC, and resorption markers NTX and CTX suggest a decreased bone metabolism in galactosemics.
aDepartment of Pediatrics, Metabolic Diseases, University Hospital Maastricht, 6202 AZ Maastricht, The Netherlands
bDepartment of Nuclear Medicine, University Hospital Maastricht, 6202 AZ Maastricht, The Netherlands
cDepartment of Biochemistry, University Hospital Maastricht, 6202 AZ Maastricht, The Netherlands
dDepartment of Clinical Biochemistry, University Hospital Maastricht, 6202 AZ Maastricht, The Netherlands
eDepartment of Clinical Epidemiology and Technology Assessment (KEMTA), University Hospital Maastricht, 6202 AZ Maastricht, The Netherlands
Corresponding author. Department of Pediatrics, Metabolic Diseases, University Hospital Maastricht, P. Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands. Fax: +31-43-387-5246.